No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta.
Julius Hollnberger, Yang Liu, Simin Xu, Silvia Chang, Ross Martin, Savrina Manhas, Thomas Aeschbacher, Bin Han, Tahmineh Yazdi, Lindsey May, Dong Han, Alex Shornikov, John Flaherty, Dmitry Manuilov, Vithika Suri, Tarik Asselah, Pietro Lampertico, Heiner Wedemeyer, Soo Aleman, Christopher Richards, Roberto Mateo, Evguenia Maiorova, Tomas Cihlar, Hongmei Mo, Stephan Urban
Journal of hepatology 2023;79(3):657-665